

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

This announcement is for information purposes only and does not constitute an offer to sell or the solicitation of an offer to buy any securities and neither this announcement nor anything herein forms the basis for any contract or commitment whatsoever. Neither this announcement nor any copy hereof may be taken into or distributed in the United States.

The information contained in this announcement is not for distribution, directly or indirectly, in or into the United States. This announcement does not constitute or form a part of any offer or solicitation to purchase or subscribe for securities in the United States. The Shares, the Existing Convertible Bonds and the Bonds mentioned herein have not been, and will not be, registered under the Securities Act, and may not be offered or sold in the United States except pursuant to registration or an exemption from the registration requirements of the Securities Act. No public offering of the Shares, the Existing Convertible Bonds or the Bonds will be made in the United States.



微創醫療科學有限公司*

(Incorporated in the Cayman Islands with limited liability)

(Stock code: 00853)

**CANCELLATION OF THE REPURCHASED
EXISTING CONVERTIBLE BONDS**

(Stock Code: 40720)

**COMPLETION OF THE ISSUE OF US\$220 MILLION 5.75 PER CENT.
CONVERTIBLE BONDS DUE 2028**

**Dealer Managers
Joint Global Coordinators and Joint Bookrunners**

J.P.Morgan



BofA SECURITIES 

Reference is made to the announcements of the Company dated 5 December 2023 and 6 December 2023 in relation to the proposed repurchase of the Existing Convertible Bonds and the proposed issue of the Bonds under the General Mandate (collectively, the “**Announcements**”). Unless the context otherwise requires, capitalised words and expressions used herein shall have the same meanings as defined in Announcements.

CANCELLATION OF THE REPURCHASED EXISTING CONVERTIBLE BONDS

As at the date of this announcement, out of the commitments to sell US\$217 million in aggregate principal amount of the Existing Convertible Bonds from holders of the Existing Convertible Bonds, the Company has, through the Dealer Managers, agreed to repurchase US\$217 million in aggregate principal amount of the Existing Convertible Bonds at the Repurchase Price. Upon completion of the Repurchase, US\$217 million in aggregate principal amount of the Existing Convertible Bonds will be cancelled on or about the date of this announcement, with the remaining outstanding Existing Convertible Bonds amounting to approximately US\$448 million.

COMPLETION OF THE ISSUE OF US\$220 MILLION 5.75 PER CENT. CONVERTIBLE BONDS DUE 2028

The Board announces that all the conditions precedent to the issue of the Bonds under the Subscription Agreement have been satisfied and the completion of the issue of the Bonds in the aggregate principal amount of US\$220 million took place on 19 December 2023.

LISTING OF THE BONDS AND THE CONVERSION SHARES ON THE HONG KONG STOCK EXCHANGE

Permission for the listing of, and dealing in, the Bonds are expected to become effective on 20 December 2023. Approval for the listing of, and permission to deal in, the Conversion Shares has been granted by the Hong Kong Stock Exchange.

By Order of the Board
MicroPort Scientific Corporation
Dr. Zhaohua Chang
Chairman

Shanghai, the PRC, 19 December 2023

As at the date of this announcement, the executive Director of the Company is Dr. Zhaohua Chang; the non-executive Directors are Mr. Hiroshi Shirafuji, Mr. Norihiro Ashida, Ms. Weiqin Sun, Dr. Qiyi Luo and Mr. Bo Peng; and the independent non-executive Directors are Mr. Jonathan H. Chou, Dr. Guoen Liu and Mr. Chunyang Shao.

* *For identification purpose only.*